Mauna Kea Technologies Reports Full Year 2023 Sales of €10.5m, Up +42%1 vs 2022

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its unaudited sales for the fourth quarter and full year 2023, ended December 31, 2023. Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: “In addition to advancing important strategic relationships with announced development partners Tasly